Biophytis seeks US FDA approval to initiate SARA-31 phase 3 study in sarcopenia

Biophytis seeks US FDA approval to initiate SARA-31 phase 3 study in sarcopenia

By, Admin 12 July 2023

Biophytis SA, a clinical-stage biotechnology company, announced that it has filed for approval on the Food and Drug Administration (FDA) portal to launch its SARA-31 programme in the US, the first ever phase 3 study in sarcopenia. The launch of the phase 3 programme follows promising results from the SARA-INT phase 2b study and discussions with health authorities in 2022. Based on the results of the previous study and feedback from the US government agency, Biophytis is starting its phase 3 program by filing the first ever phase 3 application (SARA-31) in sarcopenia with the FDA. This follows the recent submission to the European Medicines Agency. The objective of the SARA-31 phase 3 study in sarcopenia is to evaluate the efficacy and safety of Sarconeos (BIO101) in the treatment of sarcopenic patients at risk of mobility disability. Approximately 900 patients over 65 years of age with severe sarcopenia (3 = SPPB = 7) with low walking speed (4-m Gait speed = 0.8 m/s) and low grip strength (HGS < 20kg for women and < 35.5 kg for men) will be included. They will be treated for a minimum of 12 months and a maximum of 36 months, receiving either placebo or 350mg of Sarconeos (BIO101) twice daily. The primary endpoint will be the assessment of the risk of major mobility disability (MMD), measured by the ability to walk 400m in less than 15 minutes over time. In addition to this primary endpoint, the following secondary endpoints will be assessed: walking speed (4-m walking speed from the Short Physical Performance Battery (SPPB) test), handgrip strength (HGS) and patient-reported quality of life (Patient Reported Outcome SarQol, a questionnaire developed specifically for sarcopenia). Biophytis expects a response from the regulatory authorities during the third quarter of 2023, which would enable Biophytis to initiate the study in the United States. The principal investigator will be Roger A. Fielding, PhD, who heads the Nutrition, Physiology, Exercise and Sarcopenia (NEPS) Laboratory at Tufts University in Boston. Stanislas Veillet, chairman and CEO of Biophytis stated:

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!